An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein
The third outbreak of coronavirus (CoV) infection (after SARS-CoV and MERS-CoV) caused by a novel CoV (SARS-CoV-2) of the genus Beta-coronavirus has become a global pandemic. CoVs are enveloped viruses whose proteins include spike (S), membrane (M), and envelope (E) which are embedded in the viral e...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1787066 |
| _version_ | 1797633729609334784 |
|---|---|
| author | Abdolkarim Sheikhi Mohammad Hojjat-Farsangi |
| author_facet | Abdolkarim Sheikhi Mohammad Hojjat-Farsangi |
| author_sort | Abdolkarim Sheikhi |
| collection | DOAJ |
| description | The third outbreak of coronavirus (CoV) infection (after SARS-CoV and MERS-CoV) caused by a novel CoV (SARS-CoV-2) of the genus Beta-coronavirus has become a global pandemic. CoVs are enveloped viruses whose proteins include spike (S), membrane (M), and envelope (E) which are embedded in the viral envelope. The glycosylated S protein, which forms homo-trimeric spikes on the surface of the viral particle, mediates viral entry into host cells. SARS-CoV-2, like SARS-CoV, uses the Angiotensin-Converting Enzyme 2 (ACE2) cell surface protein for cellular entry. An attractive anti-viral approach is targeting virus entry into cells, for which three strategies are suggested: 1) direct targeting of the viral glycoprotein; 2) targeting the viral receptor on the cell surface; and 3) using soluble (s) ACE2 that binds to S protein thereby neutralizing the virus. In this article, the advantages and disadvantages of these strategies are explained. Moreover, we propose that fusion of the sACE2 to anti-CD16 to produce a bi-specific molecule could be a promising anti-viral strategy. |
| first_indexed | 2024-03-11T11:57:56Z |
| format | Article |
| id | doaj.art-99fc9041294348aa97680668a6677e6d |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:57:56Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-99fc9041294348aa97680668a6677e6d2023-11-08T11:55:19ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-01-01171929710.1080/21645515.2020.17870661787066An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike proteinAbdolkarim Sheikhi0Mohammad Hojjat-Farsangi1School of Medicine, Dezful University of Medical SciencesKarolinska InstituteThe third outbreak of coronavirus (CoV) infection (after SARS-CoV and MERS-CoV) caused by a novel CoV (SARS-CoV-2) of the genus Beta-coronavirus has become a global pandemic. CoVs are enveloped viruses whose proteins include spike (S), membrane (M), and envelope (E) which are embedded in the viral envelope. The glycosylated S protein, which forms homo-trimeric spikes on the surface of the viral particle, mediates viral entry into host cells. SARS-CoV-2, like SARS-CoV, uses the Angiotensin-Converting Enzyme 2 (ACE2) cell surface protein for cellular entry. An attractive anti-viral approach is targeting virus entry into cells, for which three strategies are suggested: 1) direct targeting of the viral glycoprotein; 2) targeting the viral receptor on the cell surface; and 3) using soluble (s) ACE2 that binds to S protein thereby neutralizing the virus. In this article, the advantages and disadvantages of these strategies are explained. Moreover, we propose that fusion of the sACE2 to anti-CD16 to produce a bi-specific molecule could be a promising anti-viral strategy.http://dx.doi.org/10.1080/21645515.2020.1787066covid-19sars-cov-2sace2cd16sace2-anti-cd16 |
| spellingShingle | Abdolkarim Sheikhi Mohammad Hojjat-Farsangi An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein Human Vaccines & Immunotherapeutics covid-19 sars-cov-2 sace2 cd16 sace2-anti-cd16 |
| title | An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein |
| title_full | An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein |
| title_fullStr | An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein |
| title_full_unstemmed | An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein |
| title_short | An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein |
| title_sort | immunotherapeutic method for covid 19 patients a soluble ace2 anti cd16 vhh to block sars cov 2 spike protein |
| topic | covid-19 sars-cov-2 sace2 cd16 sace2-anti-cd16 |
| url | http://dx.doi.org/10.1080/21645515.2020.1787066 |
| work_keys_str_mv | AT abdolkarimsheikhi animmunotherapeuticmethodforcovid19patientsasolubleace2anticd16vhhtoblocksarscov2spikeprotein AT mohammadhojjatfarsangi animmunotherapeuticmethodforcovid19patientsasolubleace2anticd16vhhtoblocksarscov2spikeprotein AT abdolkarimsheikhi immunotherapeuticmethodforcovid19patientsasolubleace2anticd16vhhtoblocksarscov2spikeprotein AT mohammadhojjatfarsangi immunotherapeuticmethodforcovid19patientsasolubleace2anticd16vhhtoblocksarscov2spikeprotein |